Cannabinoids (CBDs) are gaining popularity in both the skin care industry and the dermatology drug market and are becoming increasingly available to physicians and consumers. Cannabis-based personal care products suddenly seem ubiquitous all over the market, where CBD is a featured ingredient in everything from moisturizers and lotions to makeup.1 In medical dermatology, CBD has been studied in acne, eczematous disorders, lichen planus, melanoma and nonmelanoma skin cancer, melasma, prurigo, pruritus, psoriasis, scleroderma and systemic sclerosis, and seborrheic dermatitis.2
Although some of these studies indicate a potential therapeutic benefit in skin disease, existing studies are, unfortunately, underpowered and lack rigorous design. Making matters worse, the federal government lists cannabis as a schedule I substance (defined as drugs with no currently accepted medical use and a high potential for abuse), which makes it very difficult to study CBD for medical purposes. In its last communication on CBD products in the current market, the FDA stated that the existing regulatory framework for CBD is not appropriate and that it will work with Congress to develop a safe and effective regulation strategy. Despite these issues, CBD may offer a promising new area of pharmacology for skin disease and skin care. Even if dermatology providers choose not to use or recommend these products, patients are asking about them during their office visits. Therefore, it is important to…
Original Author Link click here to read complete story..